Photoactivatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy
- PMID: 35793475
- DOI: 10.1002/adma.202204765
Photoactivatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy
Erratum in
-
Correction to "Photoactivatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy".Adv Mater. 2025 Jun;37(24):e2505455. doi: 10.1002/adma.202505455. Epub 2025 Apr 1. Adv Mater. 2025. PMID: 40166856 No abstract available.
Abstract
Immunotherapy has delivered impressive outcomes in combating tumor malignancies. However, insufficient immune infiltration and poor immunogenicity within the tumor microenvironment (TME) greatly compromise patient response rates. Here, a photoactivatable silencing extracellular vesicle (PASEV) is developed for sensitized cancer immunotherapy. p21-Activated kinase 4 (PAK4) is a newly identified tumor-cell-intrinsic "guard" associated with immune exclusion. Small interfering RNA against PAK4 (siPAK4) is designed and assembled with a photoactivatable reactive-oxygen-species (ROS)-sensitive polymer to form the nanocomplex core, which is further camouflaged by extracellular vesicles from M1 macrophages. The PASEV not only serves as a vehicle for packaging, tumor accumulation, and ROS-responsive release of siPAK4 for potent PAK4 silencing, but also primes the TME through immunogenic phototherapy, thereby simultaneously boosting intratumoral infiltration and immune activation. The combined immunotherapy elicits robust anticancer immunity, thus showing great promise for fighting cancers. This work opens a new avenue to simultaneously boost intratumoral infiltration and immune activation for sensitized cancer immunotherapy.
Keywords: PAK4; RNA interference; cancer immunotherapy; extracellular vesicles; immunogenic phototherapy.
© 2022 Wiley-VCH GmbH.
References
-
- J. Nam, S. Son, K. S. Park, W. Zou, L. D. Shea, J. J. Moon, Nat. Rev. Mater. 2019, 4, 398.
-
- O. Demaria, S. Cornen, M. Daeron, Y. Morel, R. Medzhitov, E. Vivier, Nature 2019, 574, 45.
-
- T. K. Kim, E. N. Vandsemb, R. S. Herbst, L. Chen, Nat. Rev. Drug Discovery 2022, 21, 529.
-
- P. Sharma, S. Hu-Lieskovan, J. A. Wargo, A. Ribas, Cell 2017, 168, 707.
-
- L. Jerby-Arnon, P. Shah, M. S. Cuoco, C. Rodman, M. J. Su, J. C. Melms, R. Leeson, A. Kanodia, S. Mei, J. R. Lin, S. Wang, B. Rabasha, D. Liu, G. Zhang, C. Margolais, O. Ashenberg, P. A. Ott, E. I. Buchbinder, R. Haq, F. S. Hodi, G. M. Boland, R. J. Sullivan, D. T. Frederick, B. Miao, T. Moll, K. T. Flaherty, M. Herlyn, R. W. Jenkins, R. Thummalapalli, M. S. Kowalczyk, et al., Cell 2018, 175, 984.
MeSH terms
Substances
Grants and funding
- 2021YFA1201000/National Key Research and Development Program of China
- 2021YFE0106900/National Key Research and Development Program of China
- 2018YFE0117800/National Key Research and Development Program of China
- 7214283/Beijing Natural Science Foundation
- 7214302/Beijing Natural Science Foundation
- 32101157/National Natural Science Foundation of China
- 31871003/National Natural Science Foundation of China
- 32171394/National Natural Science Foundation of China
- 32001008/National Natural Science Foundation of China
- 82104105/National Natural Science Foundation of China
- 32030060/National Natural Science Foundation of China
- 51861135103/National Natural Science Foundation of China
- 2020M670169/China Postdoctoral Science Foundation
- 19JCZDJC64100/Beijing-Tianjin-Hebei Basic Research Cooperation Project
- Z201100006820005/Beijing Nova Program from Beijing Municipal Science & Technology Commission
LinkOut - more resources
Full Text Sources
Medical
Research Materials
